{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-005190","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.941677+00:00","generated_at":"2026-05-26T07:57:53.564200+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Insmed reports Q4 ARIKAYCE revenue $104.4M; brensocatib NDA accepted with Priority Review","bullets":["Full-year 2024 ARIKAYCE revenue $363.7M (+19% YoY); Q4 net loss $235.5M ($1.32/share).","Brensocatib NDA for bronchiectasis accepted by FDA with Priority Review; PDUFA date Aug 12, 2025.","Company reiterates FY2025 ARIKAYCE revenue guidance $405M–$425M (11-17% YoY growth).","Cash, equivalents, and marketable securities approx. $1.4B as of Dec 31, 2024.","Director Alfred Altomari will not stand for re-election at 2025 Annual Meeting; no disagreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-005190","json":"https://secwatch.observer/filing/0001140361-25-005190.json","markdown":"https://secwatch.observer/filing/0001140361-25-005190.md","text":"https://secwatch.observer/filing/0001140361-25-005190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/0001140361-25-005190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/ef20043928_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T07:57:53.564200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d28535c91","claim":"Alfred Altomari departed as Director at INSMED Inc.","evidence_excerpt":"On February 18, 2025, Alfred Altomari notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125005190/0001140361-25-005190-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}